Natixis Advisors
PCRX icon

Natixis Advisors’s Pacira BioSciences PCRX Stock Holding History

Natixis Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$437K Sell
17,248
-8,308
-33% -$196K ﹤0.01% 1722
2026
Q1 		$578K Buy
25,556
+13,569
+113% +$302K ﹤0.01% 1509
2025
Q4 		$310K Sell
11,987
-4,125
-26% -$98.1K ﹤0.01% 1545
2025
Q3 		$415K Buy
16,112
+2,905
+22% +$71.4K ﹤0.01% 1536
2025
Q2 		$316K Buy
13,207
+68
+0.5% +$1.71K ﹤0.01% 1541
2025
Q1 		$327K Buy
+13,139
New +$315K ﹤0.01% 1534
2024
Q3 		– Sell
-11,413
Closed -$327K – 1632
2024
Q2 		$327K Sell
11,413
-404
-3% -$11.5K ﹤0.01% 1509
2024
Q1 		$345K Buy
+11,817
New +$363K ﹤0.01% 1454
2023
Q3 		– Sell
-11,993
Closed -$481K – 1518
2023
Q2 		$481K Buy
11,993
+1,638
+16% +$67.7K ﹤0.01% 1344
2023
Q1 		$423K Buy
+10,355
New +$412K ﹤0.01% 1354
2022
Q4 		– Sell
-12,515
Closed -$666K – 1498
2022
Q3 		$666K Buy
+12,515
New +$696K ﹤0.01% 1211
2022
Q2 		– Sell
-12,898
Closed -$984K – 1494
2022
Q1 		$984K Buy
12,898
+2,381
+23% +$159K ﹤0.01% 1137
2021
Q4 		$633K Buy
+10,517
New +$580K ﹤0.01% 1203
2020
Q4 		– Sell
-38,528
Closed -$2.32M – 1237
2020
Q3 		$2.32M Buy
38,528
+1,894
+5% +$110K 0.01% 752
2020
Q2 		$1.92M Buy
36,634
+15,228
+71% +$636K 0.01% 813
2020
Q1 		$718K Buy
+21,406
New +$889K 0.01% 980

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Natixis Advisors's PCRX Position: Q2 2026 in Review

Natixis Advisors reduced its Pacira BioSciences (PCRX) stake by 33% in Q2 2026, selling an estimated $196K and leaving 17,248 shares worth $437K. The position accounts for ﹤0.01% of the portfolio, ranked #1722.

Natixis Advisors first reported a position in PCRX in Q1 2020 and has held it in 16 quarters since. The position peaked at $2.32M in Q3 2020. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Natixis Advisors held 17,248 shares of Pacira BioSciences worth $437K as of Q2 2026.
  • Natixis Advisors sold 8,308 Pacira BioSciences shares in Q2 2026, an estimated $196K.
  • Pacira BioSciences made up ﹤0.01% of Natixis Advisors's portfolio in Q2 2026, its #1722 holding.
  • Natixis Advisors first reported a position in Pacira BioSciences in Q1 2020 and has held it in 16 quarters since.
  • Natixis Advisors's Pacira BioSciences position peaked at $2.32M in Q3 2020.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.